Naphthylamide Aurora B Inhibitor for Brain Tumor Penetration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-angiogenic drugs targeting VEGFR pathways cause hypertension as a common toxic side effect, and existing Aurora B kinase inhibitors exhibit weak inhibitory activity, limiting their therapeutic effect on tumors. Additionally, these drugs struggle to cross the blood-brain barrier for effective treatment of central nervous system tumors.

Innovation Solution

A naphthylamide compound with a specific structure is developed, demonstrating higher selectivity for Aurora B kinase than VEGFR2, offering enhanced inhibitory activity and the ability to cross the blood-brain barrier.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If VEGFR inhibitors are used to treat solid tumors, then anti-angiogenic therapeutic effect is improved, but hypertension side effect occurs

Engineering Contradiction:

Improveanti-angiogenic therapeutic effectVSAvoidhypertension side effect

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates the harmful VEGFR inhibition activity from the compound while retaining the desired Aurora B kinase inhibition activity. The naphthylamide compound is designed to selectively inhibit Aurora B kinase without significantly inhibiting VEGFR, thereby removing the cause of hypertension side effects while preserving anti-tumor efficacy through a different mechanism.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The compound exhibits selective kinase inhibition with high local quality - it specifically targets Aurora B kinase with IC50 values of 0.01-10 μM while showing minimal inhibition of VEGFR. This selective action profile ensures that the therapeutic effect is achieved through Aurora B inhibition without the harmful hypertension side effects associated with VEGFR inhibition.

Inventive Principle:

Principle #3Local quality

2Reliability

If existing Aurora B kinase inhibitors are used, then tumor cell proliferation is inhibited, but inhibitory activity is weak

Engineering Contradiction:

Improveinhibitory activity against tumor cell proliferationVSAvoidinhibitory activity strength

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent optimizes the chemical structure parameters of the naphthylamide compound to achieve potent Aurora B kinase inhibition. By modifying the naphthylamide core structure and substituent groups, the compound achieves IC50 values of 0.01-10 μM against Aurora B kinase, significantly improving inhibitory activity compared to existing weak inhibitors.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If conventional anti-tumor drugs are used, then tumor growth is inhibited, but ability to cross blood-brain barrier is insufficient

Engineering Contradiction:

Improveanti-tumor efficacyVSAvoidblood-brain barrier permeability

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent modifies the physicochemical parameters of the naphthylamide compound, including molecular weight, lipophilicity, and hydrogen bonding capacity, to enhance blood-brain barrier penetration. These parameter optimizations enable the compound to effectively reach central nervous system tumors while maintaining potent Aurora B kinase inhibition activity.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP4644374A1Naphthylamide compound, and preparation method therefor and use thereof

Publication Date: 2025.11.05 SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD

Figure 1

AI summary

A naphthylamide compound as represented by formula (I), a preparation method therefor, and the use thereof in the treatment and/or prevention of diseases related to the biological activity of the protein kinase.